Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.
Company profile
Ticker
ABOS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...
SEC CIK
ABOS stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
1 Feb 23
8-K
Departure of Directors or Certain Officers
4 Jan 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Acumen Pharmaceuticals Reports Third Quarter 2022
14 Nov 22
8-K
Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted
24 Oct 22
8-K
Regulation FD Disclosure
12 Sep 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights
15 Aug 22
8-K
Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimer’s disease
1 Aug 22
EFFECT
Notice of effectiveness
11 Jul 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 157.54 mm | 157.54 mm | 157.54 mm | 157.54 mm | 157.54 mm | |
| Cash burn (monthly) | (no burn) | (no burn) | 3.79 mm | 3.28 mm | 691.58 k | |
| Cash used (since last report) | n/a | n/a | 16.38 mm | 14.19 mm | 2.99 mm | |
| Cash remaining | n/a | n/a | 141.16 mm | 143.35 mm | 154.55 mm | |
| Runway (months of cash) | n/a | n/a | 37.2 | 43.7 | 223.5 | |
Institutional ownership, Q3 2022
78.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 53 |
| Opened positions | 16 |
| Closed positions | 12 |
| Increased positions | 16 |
| Reduced positions | 11 |
| 13F shares | Current |
|---|---|
| Total value | 319.10 mm |
| Total shares | 31.65 mm |
| Total puts | 11.80 k |
| Total calls | 382.80 k |
| Total put/call ratio | 0.0 |
| Largest owners | Shares | Value |
|---|---|---|
| Ra Capital Management | 9.77 mm | $98.00 mm |
| Deep Track Capital | 3.78 mm | $37.90 mm |
| Sands Capital Ventures | 3.42 mm | $34.27 mm |
| Paul B Manning | 3.04 mm | $20.55 mm |
| Laurion Capital Management | 1.21 mm | $12.10 mm |
| Great Point Partners | 1.20 mm | $12.04 mm |
| Sands Capital Ventures Discovery Fund III | 1.15 mm | $23.15 mm |
| BLK Blackrock | 1.12 mm | $11.18 mm |
| Commodore Capital | 1.10 mm | $11.03 mm |
| Vanguard | 651.05 k | $6.53 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 Jan 23 | Russell Barton | Common Stock | Grant | Acquire A | No | No | 0 | 26,700 | 0.00 | 26,700 |
| 17 Jan 23 | Russell Barton | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 6.11 | 120,200 | 734.42 k | 120,200 |
| 17 Jan 23 | Derek M Meisner | Common Stock | Grant | Acquire A | No | No | 0 | 26,800 | 0.00 | 26,800 |
| 17 Jan 23 | Derek M Meisner | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 6.11 | 120,800 | 738.09 k | 120,800 |
| 17 Jan 23 | Daniel Joseph OConnell | Common Stock | Grant | Acquire A | No | No | 0 | 114,000 | 0.00 | 116,685 |
| 17 Jan 23 | Daniel Joseph OConnell | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 6.11 | 472,500 | 2.89 mm | 472,500 |
| 17 Jan 23 | Eric Siemers | Common Stock | Grant | Acquire A | No | No | 0 | 26,700 | 0.00 | 26,700 |
| 17 Jan 23 | Eric Siemers | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 6.11 | 120,200 | 734.42 k | 120,200 |
| 17 Jan 23 | Matt Zuga | Common Stock | Grant | Acquire A | No | No | 0 | 33,500 | 0.00 | 109,687 |
| 17 Jan 23 | Matt Zuga | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 6.11 | 150,800 | 921.39 k | 150,800 |
News
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
2 Feb 23
'Here's Where To Look For The Next Developments In The Fight Against Alzheimer's Disease' - CNBC
17 Jan 23
5 Value Stocks In The Healthcare Sector
26 Dec 22
Overview Of Value Stocks In The Healthcare Sector
28 Nov 22
Credit Suisse Maintains Outperform on Acumen Pharmaceuticals, Lowers Price Target to $16
15 Nov 22